ALPHA-D3

ALPHA-D3 is an investigational therapeutic candidate developed by Filamon, primarily focused on inhibiting the epithelial-mesenchymal transition (EMT) process. It is being developed for the treatment of various solid tumors—including lung, breast, prostate, and pancreatic cancers—as well as chronic fibrotic diseases such as kidney and liver fibrosis. The drug's mechanism of action involves the degradation of the Epidermal Growth Factor Receptor (EGFR), inhibition of the intermediate filament protein vimentin, and the blockade of protein responses to inflammation. By targeting these pathways, ALPHA-D3 aims to reverse the mesenchymal phenotype of aggressive cancer cells and fibrotic tissue, potentially limiting metastasis and organ scarring. It is often compared to Filamon's other lead asset, KESONOTIDE, for relative efficacy across different cancer types.

Other names

ALPHA-D3ALPHA-D-3ALPHA-D 3